Media coverage about Bioptix (NASDAQ:BIOP) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioptix earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news headlines about the technology company an impact score of 45.3684775800969 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern’s analysis:

Shares of Bioptix (NASDAQ:BIOP) opened at 7.40 on Friday. Bioptix has a 1-year low of $3.02 and a 1-year high of $9.50. The firm’s market capitalization is $40.23 million. The company’s 50-day moving average is $5.13 and its 200 day moving average is $5.13.

The firm also recently declared a special dividend, which will be paid on Wednesday, October 18th. Stockholders of record on Friday, October 13th will be given a dividend of $1.00 per share. The ex-dividend date of this dividend is Thursday, October 12th.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at

Bioptix Company Profile

Riot Blockchain Inc, formerly Bioptix, Inc, is intends to gain exposure to the blockchain ecosystem through targeted investments in the sector, with a primary focus on the bitcoin and Ethereum blockchains. The Company also provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions.

Insider Buying and Selling by Quarter for Bioptix (NASDAQ:BIOP)

Receive News & Ratings for Bioptix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioptix Inc. and related companies with's FREE daily email newsletter.